Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC-IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study.
Raspagliesi F, Bogani G, Matteucci L, Casarin J, Sabatucci I, Tamberi S, Arcangeli V, Maltese G, Lepori S, Comerci G, Stefanetti M, Ditto A, Martinelli F, Chiappa V, Lorusso D. Raspagliesi F, et al. Among authors: arcangeli v. Int J Gynecol Cancer. 2018 Nov;28(9):1706-1713. doi: 10.1097/IGC.0000000000001286. Int J Gynecol Cancer. 2018. PMID: 30376554
Carboplatin and gemcitabine in the palliative treatment of stage IV non-small cell lung cancer: definitive results of a phase II trial.
Tassinari D, Fochessati F, Arcangeli V, Sartori S, Agostini V, Fantini M, Genestreti G, Grassia S, Ioli G, Imola M, Iorio D, Mianulli AM, Monticelli G, Oliverio G, Panzini I, Papi M, Poggi B, Polselli A, Pulini S, Tamburini E, Fattori PP, Ravaioli A. Tassinari D, et al. Among authors: arcangeli v. Tumori. 2004 Jan-Feb;90(1):54-9. doi: 10.1177/030089160409000113. Tumori. 2004. PMID: 15143973 Clinical Trial.
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO 11 investigators. Pignata S, et al. Among authors: arcangeli v. Lancet Oncol. 2015 May;16(5):561-8. doi: 10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14. Lancet Oncol. 2015. PMID: 25882986 Free article. Clinical Trial.
The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study.
Bogani G, Matteucci L, Tamberi S, Arcangeli V, Ditto A, Maltese G, Signorelli M, Martinelli F, Chiappa V, Leone Roberti Maggiore U, Perotto S, Scaffa C, Comerci G, Stefanetti M, Raspagliesi F, Lorusso D. Bogani G, et al. Among authors: arcangeli v. Int J Gynecol Cancer. 2017 Nov;27(9):1856-1862. doi: 10.1097/IGC.0000000000001108. Int J Gynecol Cancer. 2017. PMID: 29064913
RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.
Bogani G, Matteucci L, Tamberi S, Ditto A, Sabatucci I, Murgia F, Arcangeli V, Maltese G, Comerci G, Stefanetti M, Sonetto C, Calareso G, Marchiano A, Chiappa V, Lorusso D, Raspagliesi F. Bogani G, et al. Among authors: arcangeli v. Eur J Obstet Gynecol Reprod Biol. 2019 Jun;237:93-99. doi: 10.1016/j.ejogrb.2019.04.007. Epub 2019 Apr 8. Eur J Obstet Gynecol Reprod Biol. 2019. PMID: 31029972
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Lorusso D, Bologna A, Cecere SC, De Matteis E, Scandurra G, Zamagni C, Arcangeli V, Artioli F, Bella M, Blanco G, Cardalesi C, Casartelli C, De Vivo R, Di Napoli M, Gisone EB, Lauria R, Lissoni AA, Loizzi V, Maccaroni E, Mangili G, Marchetti C, Martella F, Naglieri E, Parolin V, Ricciardi G, Ronzino G, Salutari V, Scarfone G, Secondino S, Spagnoletti I, Tasca G, Tognon G, Guarneri V. Lorusso D, et al. Among authors: arcangeli v. Support Care Cancer. 2020 May;28(5):2435-2442. doi: 10.1007/s00520-020-05320-4. Epub 2020 Feb 11. Support Care Cancer. 2020. PMID: 32048043
Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Grandi G, Perrone AM, Perrone A, Mandato VD, Comerci G, Sammarini M, Merisio C, Amadori A, Stefanetti M, Martinello R, Facchinetti F, De Iaco P; Brca Emilia-Romagna Gyneco-Oncological (BERGO) Collaborative Group. Grandi G, et al. Maturitas. 2021 Jan;143:59-64. doi: 10.1016/j.maturitas.2020.08.011. Epub 2020 Aug 31. Maturitas. 2021. PMID: 33308637
Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer.
Rapposelli IG, Zampiga V, Cangini I, Arcangeli V, Ravegnani M, Valgiusti M, Pini S, Tamberi S, Bartolini G, Passardi A, Martinelli G, Calistri D, Frassineti GL, Falcini F, Danesi R. Rapposelli IG, et al. Among authors: arcangeli v. BMC Cancer. 2021 May 26;21(1):611. doi: 10.1186/s12885-021-08368-5. BMC Cancer. 2021. PMID: 34034685 Free PMC article.
Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients.
Gurioli G, Tedaldi G, Farolfi A, Petracci E, Casanova C, Comerci G, Danesi R, Arcangeli V, Ravegnani M, Calistri D, Zampiga V, Cangini I, Fonzi E, Virga A, Tassinari D, Rosati M, Ulivi P, De Giorgi U. Gurioli G, et al. Among authors: arcangeli v. Int J Mol Sci. 2022 Dec 13;23(24):15789. doi: 10.3390/ijms232415789. Int J Mol Sci. 2022. PMID: 36555431 Free PMC article.
59 results